GBT Announces Participation at the Cantor Global Healthcare Conference
Global Blood Therapeutics, Inc. (GBT) announced its participation in a virtual fireside chat at the Cantor Global Healthcare Conference on September 27, 2021, at 2:40 p.m. ET. The chat will be available to stream live on GBT's website, with an archived replay accessible for a month after the event. GBT focuses on developing treatments for sickle cell disease (SCD), having launched its first FDA-approved treatment, Oxbryta, and advancing its pipeline with inclacumab and GBT021601 for SCD. For more information, visit www.gbt.com.
- Participation in a notable healthcare conference can enhance visibility and investor interest.
- Advancing a Phase 3 program for inclacumab may lead to future revenues if successful.
- None.
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Cantor Global Healthcare Conference on Monday, September 27, 2021, at 2:40 p.m. ET.
The fireside chat will be webcast live from GBT’s website at www.gbt.com in the Investors section. A replay of the webcast will be archived and available for one month following the event.
About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase 3 development to address pain crises associated with the disease, and GBT021601 (GBT601), the company’s next-generation hemoglobin S polymerization inhibitor. In addition, GBT’s drug discovery teams are working on new targets to develop the next wave of potential treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.
Contact:
Steven Immergut (media)
650-410-3258
simmergut@gbt.com
Courtney Roberts (investors)
650-351-7881
croberts@gbt.com
FAQ
When is GBT's fireside chat at the Cantor Global Healthcare Conference?
Where can I watch GBT's fireside chat?
What is GBT's main focus?
What is Oxbryta?
What is inclacumab?
